Publication:
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

1

Issued Date

2021-10-01

Resource Type

Article

ISSN

19360541
19360533

DOI

10.1007/s12072-021-10239-x

Other identifier(s)

2-s2.0-85113351403

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Hepatology International. Vol.15, No.5 (2021), 1031-1048

Suggested Citation

George Lau, Ming Lung Yu, Grace Wong, Alexander Thompson, Hasmik Ghazinian, Jin Lin Hou, Teerha Piratvisuth, Ji Dong Jia, Masashi Mizokami, Gregory Cheng, Guo Feng Chen, Zhen Wen Liu, Oidov Baatarkhuu, Ann Lii Cheng, Woon Leung Ng, Patrick Lau, Tony Mok, Jer Ming Chang, Saeed Hamid, A. Kadir Dokmeci, Rino A. Gani, Diana A. Payawal, Pierce Chow, Joong Won Park, Simone I. Strasser, Rosmawaiti Mohamed, Khin Maung Win, Tanwandee Tawesak, Shiv Kumar Sarin, Masao Omata APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatology International. Vol.15, No.5 (2021), 1031-1048. doi:10.1007/s12072-021-10239-x Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/77819

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

Author(s)

George Lau
 Ming Lung Yu
 Grace Wong
 Alexander Thompson
 Hasmik Ghazinian
 Jin Lin Hou
 Teerha Piratvisuth
 Ji Dong Jia
 Masashi Mizokami
 Gregory Cheng
 Guo Feng Chen
 Zhen Wen Liu
 Oidov Baatarkhuu
 Ann Lii Cheng
 Woon Leung Ng
 Patrick Lau
 Tony Mok
 Jer Ming Chang
 Saeed Hamid
 A. Kadir Dokmeci
 Rino A. Gani
 Diana A. Payawal
 Pierce Chow
 Joong Won Park
 Simone I. Strasser
 Rosmawaiti Mohamed
 Khin Maung Win
 Tanwandee Tawesak
 Shiv Kumar Sarin
 Masao Omata

Other Contributor(s)

Siriraj Hospital
 Institute of Liver and Biliary Sciences
 Beijing Friendship Hospital, Capital Medical University
 Kaohsiung Medical University Chung-Ho Memorial Hospital
 National Taiwan University Hospital
 Mongolian National University of Medical Sciences
 General Hospital of People's Liberation Army
 Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
 National Cancer Center, Gyeonggi
 The Aga Khan University Hospital
 The University of Tokyo
 National Center for Global Health and Medicine
 University of Macau
 Royal Prince Alfred Hospital
 Singapore General Hospital
 University of Malaya Medical Centre
 Ankara Üniversitesi
 Prince of Songkla University
 Chinese University of Hong Kong
 Southern Medical University
 United Christian Hospital Hong Kong
 St. Vincent's Hospital Melbourne
 Cardinal Santos Medical Center
 Nork Clinical Hospital of Infectious Diseases
 Yangon GI and Liver Centre
 Humanity and Health Clinical Trial Center
 Yamanashi Central Hospital

Abstract

Background & Aim: Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation. Methods: All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation. Recommendations: We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/123456789/77819

Collections

Scopus 2021